| Serial Number | 79359336 |
| Word Mark | EVOX THERAPEUTICS |
| Filing Date | Thursday, December 1, 2022 |
| Status | 645 - FINAL REFUSAL - MAILED |
| Status Date | Thursday, June 20, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Pharmaceuticals, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations and substances, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered or purified exosomes for therapeutic use, including those that facilitate the delivery of pharmaceutical preparations for therapeutic use; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy, including those that facilitate the delivery of pharmaceutical preparations; medicine, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; medical preparations and articles, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations for medical purposes, including for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies, including mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; biological preparations comprising exosome, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations comprising a therapeutic target protein-loaded exosome, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological preparations comprising exosome for pharmaceutical purposes, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; biological reagents for medical use, including drug delivery agents in the form of exosomes that facilitate the delivery of pharmaceutical preparations; mixed biological preparations for medical purposes, including for the prevention and treatment of infectious diseases; mixed biological preparations for the prevention and treatment of infectious diseases; diagnostic reagents used in the fields of biological, genetic engineering and pharmaceutical research; diagnostic reagents comprising exosome used in the fields of biological, genetic engineering and pharmaceutical research; pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, extracellular vesicle (EV)-based nucleic acid therapeutics for the prevention and treatment of infections or disease, including infectious diseases; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies, including including mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy |
| Goods and Services | Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; laboratory analysis service relating to the diagnosis and treatment of persons, including medical laboratory analysis service relating to the diagnosis and treatment of persons; medical analysis and examinations; medical treatment services; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases, including medical services such as medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies, including mitochondrial disease, joint and ligament strains and tears, muscle atrophy, and muscular dystrophy |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Scientific, medical and pharmaceutical research and development services; pharmaceutical drug development services; research and development of pharmaceutical preparations; research and analysis services, including those in the field of pharmaceuticals; biological research; clinical research, including in the field of transformational therapeutics; providing medical and scientific research information in the field of filtration of exosomes from blood, including providing medical research information and scientific research information all in the field of filtration of exosomes from blood; scientific investigations for medical purposes; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; research and development in the field of biotherapeutics for the treatment of infectious diseases and metabolic disorders; consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 3, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 3, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, January 3, 2023 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Evox Therapeutics Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Friday, December 30, 2022 | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB |
| Tuesday, January 3, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, January 7, 2023 | APPLICATION FILING RECEIPT MAILED |
| Monday, September 11, 2023 | ASSIGNED TO EXAMINER |
| Saturday, September 23, 2023 | NON-FINAL ACTION WRITTEN |
| Sunday, September 24, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Wednesday, October 4, 2023 | REFUSAL PROCESSED BY MPU |
| Thursday, October 5, 2023 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, October 31, 2023 | REFUSAL PROCESSED BY IB |
| Monday, November 27, 2023 | CORRECTION CREATED FOR IB |
| Thursday, April 4, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Saturday, April 6, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, November 27, 2023 | CORRECTION SENT TO IB |
| Thursday, April 4, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, June 7, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB |
| Thursday, June 20, 2024 | FINAL REFUSAL WRITTEN |
| Thursday, June 20, 2024 | FINAL REFUSAL E-MAILED |
| Thursday, June 20, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, May 14, 2024 | ASSIGNED TO EXAMINER |